Table 1.
Study population characteristics
| No pertuzumab | Pertuzumab | Overall | p-value | |
|---|---|---|---|---|
| n = 362 | n = 357 | n = 719 | ||
| Age (years) | ||||
| Mean (sd) | 51.0 (12.4) | 49.3 (9.83) | 50.1 (11.2) | 0.09 |
| Median (IQR) | 49.0 (43.0–61.0) | 49.0 (43.0–56.0) | 49.0 (43.0–58.0) | |
| HR status | ||||
| Negative | 128 (35.4%) | 137 (38.6%) | 265 (37.0%) | 0.39 |
| Positive | 234 (64.6%) | 218 (61.4%) | 452 (63.0%) | |
| Missing | N/A | 2 | 2 (0.3%) | |
| Grade | ||||
| 1–2 | 131 (36.6%) | 175 (49.0%) | 306 (42.8%) | < 0.001 |
| 3 | 227 (63.4%) | 182 (51.0%) | 409 (57.2%) | |
| Missing | 4 | 4 | ||
| cT | 0.75 | |||
| 0–2 | 250 (69.4%) | 252 (70.6%) | 502 (70.0%) | |
| 3–4 | 110 (30.6%) | 105 (29.4%) | 215 (30.0%) | |
| Missing | 2 | 0 | 2 | |
| cN | 0.007 | |||
| Negative | 106 (29.4%) | 138 (40.0%) | 244 (34.2%) | |
| Positive | 254 (70.6%) | 216 (60.0%) | 470 (65.8%) | |
| Missing | 2 | 3 | 5 | |
| HER2 IHC | 0.23 | |||
| 1+ | 1 (0.3%) | 1 (0.3%) | 2 (0.3%) | |
| 2+ | 28 (9.2%) | 19 (6.3%) | 47 (7.7%) | |
| 3+ | 276 (90.5%) | 282 (93.4%) | 558 (91.9%) | |
| Missing | 57 | 55 | 112 | |
| Anthracyclines | 0.001 | |||
| No | 134 (37.0%) | 175 (49.0%) | 309 (43%) | |
| Yes | 228 (63.0%) | 182 (51.0%) | 410 (57.0%) | |
| BluePrint Standard Subtype | 0.58 | |||
| HER2-type | 308 (85.1%) | 313 (87.7%) | 621 (86.4%) | |
| Basal-type | 6 (1.7%) | 4 (1.1%) | 10 (1.4%) | |
| Luminal-type | 48 (13.3%) | 40 (11.2%) | 88 (12.2%) | |
| BluePrint Dual Subtype | 0.54 | |||
| HER2-single-type | 279 (77.1%) | 278 (77.9%) | 557 (77.5%) | |
| Basal-single-type | 4 (1.1%) | 2 (0.6%) | 6 (0.8%) | |
| Luminal-single-type | 31 (8.6%) | 29 (8.1%) | 60 (8.3%) | |
| Luminal-HER2-type | 40 (11.0%) | 41 (11.5%) | 81 (11.3%) | |
| HER2-Basal-type | 7 (1.9%) | 4 (1.1%) | 11 (1.5%) | |
| Luminal-Basal-type | 1 (0.3%) | 0 (0%) | 1 (0.1%) | |
| Luminal-HER2-Basal-type | 0 (0%) | 3 (0.8%) | 3 (0.4%) | |
| pCR | < 0.001 | |||
| No | 205 (59.2%) | 113 (33.8%) | 318 (46.8%) | |
| Yes | 132 (38.2%) | 212 (63.5%) | 344 (50.6%) | |
| Missing | 9 (2.6%) | 9 (2.7%) | 18 (2.6%) | |
HR status hormone receptor status, cT clinical T-stage, cN clinical N-stage, HER2 IHC HER2 immunohistochemistry score